Transforming The Capital Markets

Technological and regulatory advances have played a major role in the way we as individuals and businesses receive and consume information. How has this impacted your investment landscape and the decisions you make in your portfolio? I explore this topic throughout this document while encouraging my readers to familiarize themselves with Title II of the JOBS Act.

There are a wide variety of hedge funds and venture capital funds that all claim to have the right “secret sauce” in beating the S&P 500 Index. The S&P 500 has outperformed the Bloomberg hedge fund aggregate Index for last 5 years. 2013 was the worst year on a performance basis since 2005 as hedge funds returned on average a 7.4% return vs. the SPX 29.6% return.[1] From January of 2009 through July 2014 the S&P 500 is up 113.75% or an 17.06% annualized return before dividends versus the Credit Suisse Hedge Fund Index being up 55.33% or an 8.21% annualized return before fees[2].

Venture capital funds have not been a slam-dunk investment by any stretch of the imagination either. A major study conducted by the Kauffman Foundation was released in May of 2012 and entitled “We Have Met the Enemy…. and He is Us.” The Kauffman Foundation Investment Team analyzed their 20-year history of venture investing in nearly 100 VC funds – – many of them “household name” venture funds. What they found that is that only 20 of 100 venture funds generated returns that beat a public-market equivalent by more than 3 percent annually and the majority of funds, 62 out of 100, failed to exceed returns of the S&P index funds, after management fees and carried interests were paid. In addition to delivering underperformance, many of the venture funds had lock-ups of 10 or more years[3]

The question accredited investors should be asking themselves, “Is the traditional “2 and 20” fee structure hedge and venture funds charge worth paying?” There will always be outliers and those venture and hedge fund managers that outperform their peers by a wide margin. It is naïve to make general, broad based assumptions here, but there is mounting evidence and an argument to be made that the traditional hedge and venture performance and payout models are broken. Will the “2 and 20” fee structure become a thing of the past?

The world of investing is changing in front of our very eyes, thanks in big part to the JOBS act and the incredible technological advances in the way products (including investment opportunities) are marketed. Deal Labs believes this change in the infrastructure of the investment world can potentially bring an investor more familiar opportunities on a frequent basis. Deal Labs envisions a more efficient landscape where our investors have more deal flow to choose from that is ultimately revealed to them based on attributes they possess. Upon joining our team as an accredited investor or QIB we believe it is important for our investors to begin to comprehend the major regulatory changes that are directly impacting their current investment landscapes.

The SEC issued regulations regarding Title II of the JOBS Act on September 23, 2013, which lifted the ban on general solicitation. Title II of the JOBS Act allows for private equity transactions to be marketed broadly to investors using all available media platforms (e.g. TV, radio, seminars and, most significantly, the internet) and provides accredited investors awareness of, and direct access to the types of deals that were once only known to hedge funds, venture capital firms and other institutional investors. This shift in policy could bring an unprecedented amount of capital into companies in development or in hyper-growth mode. Moreover, Deal Labs has observed that some experienced entrepreneurs who have compelling new ventures want to avoid taking venture capital, given that VCs often have a different agenda than the management at the issuer.

The accredited investor who wants access to early-stage, later-stage, and even public companies looking for new investors will no longer need to rely on the traditional channels and will therefore be able to avoid significant management and performance fees. Title II of the JOBS Act allows for a simple and compelling way to use technology to raise capital for entrepreneurs and executive management for companies and partnerships.

At Deal Labs we have identified a major market opportunity that is a product of technological trends paired with the regulatory changes previously discussed. Deal Labs uses technologies to connect businesses and partnerships with accredited investors and QIBs. Through a sophisticated stack of marketing automation, CRM technology and databases, we find investors that we believe may be well suited for a specific investment. Each investor is delivered a deal announcement providing basic information on the offering. From there, interested investors are invited to learn more about the deal through the virtual deal room – permitting the investor to make an informed decision.

Deal Labs is currently building an investor base that believes in a customized relationship and consistent access to more investment opportunities. We believe it is important to limit deal offerings to certain investors, which is why we focus on key attributes of our investors, so that those investors are suited for a particular offering. If you would like to learn more about Deal Labs please contact us at info@deallabs.com.

 

 

 

 

 

 

[1] Bloomberg:

[2] Source: Bloomberg LP

[3] Ewing Marion Kauffman Foundation: We Have Met the Enemy….and He is US, May 2012

No One Likes to be Spied on: Especially your Kids

How difficult is it to make sure your kids engage in healthy and safe social media behavior? Everyday parents face the overwhelmingly difficult task of walking a fine line between spying on their children and simply being there for them. Is it possible to promote responsible social media and mobile usage for your children without spying on them? According to Cyberbully CEO, Bill Tincup, this is exactly what Cyberbully does with its patented, Tapwize technology. Tapwize uses server-side technology which is adapted from law enforcement, and has helped law enforcement convict 1000 documented child abuse perpetrators.

The unfortunate reality of bullying is that it has grown more complicated over the past several years with the onslaught of social media and mobile phone usage. A July 27, Forbes article titled, ” The Real-World Implications Of Workplace And Cyber Bullying” by Meghan M. Biro” states:

“Fast forward to 2014, and bullying is alive and well. We’ve all read news stories about bullying, most in the context of kids in school and stories that are endless in social media channels. Some – the case where a Florida teen committed suicide after being bullied in cyberspace by as many as 15 classmates – seem incomprehensible. Even more disturbing, the two principal bullies’ parents refused to cooperate with the school and police. What parent could let such behavior go unchecked? Who could do that to another person?”

Fortunately, there are now tools available to prevent inappropriate behavior by or directed to children or young adults. Unlike competitors, TapWize is not a tool for spying on your kids but a behavioral modification service that is designed to positively change behavior while offering users a rewards system. Parents set alert parameters and are only alerted when rules are broken while a child receives real world rewards for good behavior. Recently, Cyberbully and Fandango have teamed up to provide a rewards system against online bullying. CEO, Bill Tincup has 13 years experience in the mobile technology space and has developed mobile applications for Mattel, Hallmark, and Dilbert Motorola. Cyberbully is raising $1,950,000 in a series B preferred stock round.  A majority of the funds will be used toward completing the development of their TapWize technology. The Pre-Money valuation is $8,000,000 and the minimum investment is $50,000. Please contact Deal Labs at http://www.deallabs.com.

Timing Is Everything for The True Life Companies

Bidding wars are plaguing more than just home buyers these days and The True Life Companies has been positioning itself for the past six years to benefit from a current housing crunch that has developers caught up in a real fight for land.

The True Life Companies is a diversified group of real estate companies whose primary mission is to be a premier provider of lots and land to America’s home builders. This is a convenient mission given that The True Life Companies is headquartered right here in the Bay Area where developers are faced with a sincere shortage of land to build. Developers are finding themselves at the heart of bidding wars that have served as the same catalyst of frustration for homebuyers.

In the Bay Area land costs have soared in the past couple years. Estimates include percentage increases of 40 to 50 percent in the past three years alone (Mercury News). According to Meyer’s Research (7/11/2014), the housing industry’s leading provider of rich data for residential real estate, land costs in San Jose now range from $3 to $4 million per acre. While the media reacts to dramatic price increases sending a surge of worry across the real estate industry, The True Life Companies is executing a plan to monetize their visionary thinking that began in 2008 while the market was being folded inside out.

A recent Reuters article titled, Scarce Land Could Blunt Recovery for U.S. Homebuilders (4/5/2014) highlighted that “time is running out for ambitious homebuilders short of land, who must typically spend between two and five years readying raw land for development. Land near city centers, known in the industry as ‘A’ lots, is especially hard to come by”. As an investor, I would be looking towards those who have strategically placed themselves in the middle of this bidding war holding supply that can be sold at significant premium. The macro trends that are influencing this industry seem to be currently working to the True Life Companies advantage as they continue their Western US roll out strategy. Part of this strategy includes a $5,000,000 capital raise with two LLC Membership options. Minimum investment is $100,000. The ​way to participate is through a fund managed by True Life, and it’s called the TTLC RIA 2 LLC Fund. Please contact Deal Labs by signing up at www.deallabs.com.

Deal Update: Exciting Results in the Recent Nueon Pilot Human Trial

Deal Labs is excited to announce the recent results from the Nueon Pilot Human trial.  The study included 10 human subjects (informed consent) meant to provide validation of the Nueon Reader. Study Results
 
  1. High risk subjects were properly identified
  2. Elevated risk identified in a subject with a normal cuff pressure
  3. Low risk “white coat hypertension” was properly identified
  4. An important adjunct to blood pressure cuff measurement
  5. Molecular spectroscopy provides “actionable truth” about blood pressure effects
The Nueon Reader has exceeded expectations in the first human trial.  This small study has demonstrated that the Nueon Reader can properly identify at-risk subjects and properly acquit subjects with false or “white coat” hypertension.  All signs point to the Nueon Reader being a useful adjunct in the care and management of hypertension. These results are preliminary and do not guarantee that further studies will be successful.  

“This is extremely nice data. Better than I would have predicted for sure. I think you are on to something.” Dr. Thomas Quertermous, MD

“These are phenomenal results. This small study proves the value of spectral measurements and reinforces the fact that spectroscopy does not lie.” Dr. Robert J Rosenthal, Ph. D.

Note that these MDs are independent of Deal Labs and are not compensated for expressing their opinion. These quotes represent their individual opinions based on the limited scope of the study and are not an indication that the final product will be successful. 

You can read more about the human study results online.

Nueon is still accepting offers in the $3.5M Series A (preferred stock) capital raise.  The minimum investment is $50,000 and all investors must be accredited. 

View the Nueon Deal Summary

Former GC of Tesla and Deal Labs CEO, Craig Harding, speaks with Dow Jones

Could a venture capitalist be replaced by a machine?

Probably not, but one bootstrapped San Francisco company is automating a process that is near and dear to VCs: finding syndicates of likeminded investors to put money behind a promising new technology.

Deal Labs Inc. this week announced its existence by reporting the close of its first deal that came together over its online funding platform. It is identifying and reaching out to investors with potential deals, especially investors who do not want to pay the fees that venture firms charge, which can eat into returns, said Chief Executive Craig Harding.

“A lot of investors today are looking for direct investments because a lot of times the 2-and-20 fees at venture firms are too high,” he said, referring to the typical 2% management fee and 20% carried interest that VCs collect.

Deal Labs collects a 7% commission through its broker-dealer from companies that raise funding on its platform, he said.

Though it resembles crowdfunding, Deal Labs’ model is far more targeted than that model, where an investment opportunity is presented to the world at large.

An entrepreneur in search of funding approaches Deal Labs, and Deal Labs learns about the technology in development. Mr. Harding said Deal Labs then taps various sources of data, including Data.com, to find potential investors with expertise in the same area of technology.

Deal Labs mainly pitches family offices, venture firms, wealth managers and retail, or individual, investors, he said.

Using marketing-automation software, customer-relation management software and database technology, Deal Labs then instigates a sort of high-tech matchmaking between companies in search of funding and the types of investors who are likely to back the company, he said.

In the case of Consano Medical Inc., a startup with a medical device for monitoring sepsis that became the first company to raise a funding round with Deal Labs, Deal Labs reached out to medical professionals, and in the end found a group of physicians in Texas who chipped in together and led the round, Mr. Harding said.

Consano had set out to raise a $3.2 million Series A round, and in the end raised $3.9 million from the physicians’ group and other angel investors.

Deal Labs is now announcing its second deal

Nueon Inc., a company developing a device to measure hypertension, is looking to raise around $3.4 million, and Deal Labs will again reach out to medical professionals to aid the company, Mr. Harding said.

But Deal Labs will soon branch beyond medical technology, he said, and will soon launch a campaign for mobile-game application maker F3-Apps.com and for financial compliance software maker Gordian Technology Inc.

F3 will seek to raise just under $1 million, and Gordian will seek $2 million, he added.

As Deal Labs will be reaching out to a number of entities that often become limited partners in venture funds, the company could start cutting in on the VC action, Mr. Harding said, though that has not yet happened.

A funding platform like Deal Labs only became possible last year, when the Securities and Exchange Commission relaxed some of the rules surrounding general solicitation for investments.

http://www.deallabs.com/

Write to Timothy Hay at timothy.hay@wsj.com

Document DJFVW00020140626ea6qs1n71